| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
| [2] |
Shi Y, Men X, Li X, et al. Research progress and clinical prospect of immunocytotherapy for the treatment of hepatocellular carcinoma[J]. Int Immunopharmacol, 2020(82):106351.
|
| [3] |
Chen X, Guo ZQ, Cao D, et al. Knockdown of DEPDC1B inhibits the development of glioblastoma[J]. Cancer Cell Int, 2020(20):310.
|
| [4] |
Zhang S, Shi W, Hu W, et al. DEP domain-containing protein 1B (DEPDC1B) promotes migration and invasion in pancreatic cancer through the Rac1/PAK1-LIMK1-Cofilin1 signaling pathway[J]. Onco Targets Ther, 2020(13):1481-1496.
|
| [5] |
Mosaddeghzadeh N, Ahmadian MR. The RHO family GTPases: mechanisms of regulation and signaling[J]. Cells, 2021, 10(7):1831.
|
| [6] |
Lawson CD, Ridley AJ. Rho GTPase signaling complexes in cell migration and invasion[J]. J Cell Biol, 2018, 217(2):447-457.
|
| [7] |
Bai S, Chen T, Du T, et al. High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer[J]. Oncol Lett, 2017, 14(6):6801-6808.
|
| [8] |
Xu Y, Sun W, Zheng B, et al. DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis[J]. Exp Cell Res, 2019, 379(1):48-54.
|
| [9] |
Ganesan P, Kulik LM. Hepatocellular carcinoma: new developments[J]. Clin Liver Dis, 2023, 27(1):85-102.
|
| [10] |
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
|
| [11] |
Lai CH, Xu K, Zhou J, et al. DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1[J]. Cell Death Dis, 2020, 11(11):986.
|
| [12] |
Sun Y, Zhang Z. In silico identification of crucial genes and specific pathways in hepatocellular cancer[J]. Genet Test Mol Biomarkers, 2020, 24(5):296-308.
|
| [13] |
Wang L, Tang L, Xu R, et al. DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5[J]. Cell Death Dis, 2021, 12(8):753.
|
| [14] |
Su YF, Liang CY, Huang CY, et al. A putative novel protein, DEPDC1B, is overexpressed in oral cancer patients, and enhanced anchorage-independent growth in oral cancer cells that is mediated by Rac1 and ERK[J]. J Biomed Sci, 2014, 21(1):67.
|
| [15] |
Kikuchi R, Sampetrean O, Saya H, et al. Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells[J]. J Neurooncol, 2017, 133(2):297-307.
|
| [16] |
Dang XW, Pan Q, Lin ZH, et al. Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1[J]. Aging, 2021, 13(16):20094-20115.
|
| [17] |
Shen E, Zhang J, Lu Y. DEP domain containing 1B (DEPDC1B) exerts the tumor promoter in hepatocellular carcinoma through activating p53 signaling pathway via kinesin family member 23 (KIF23)[J]. Bioengineered, 2022, 13(1):1103-1114.
|
| [18] |
Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma[J]. Liver Transplant, 2005, 11(9):1086-1092.
|
| [19] |
Xu S, Zhan M, Wang J. Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks[J]. Cell Death Discov, 2017(3):17069.
|
| [20] |
Sengez B, Carr BI, Alotaibi H. EMT and inflammation: crossroads in HCC[J]. J Gastrointest Cancer, 2023, 54(1):204-212.
|
| [21] |
Liu X, Li T, Huang X, et al. DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway[J]. Oncol Lett, 2020, 20(5):146.
|